Stay updated on GCS-100 Weekly Dosing in Chronic Kidney Disease Clinical Trial
Sign up to get notified when there's something new on the GCS-100 Weekly Dosing in Chronic Kidney Disease Clinical Trial page.

Latest updates to the GCS-100 Weekly Dosing in Chronic Kidney Disease Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page adds Revision: v3.4.2 and removes a governmental funding notice and an older Revision: v3.4.1; these are site-maintenance updates that do not affect core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check26 days agoChange DetectedThe page now includes a government funding lapse notice with status guidance and shows the revision as v3.4.1, replacing the previous v3.4.0 revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check33 days agoChange DetectedShow glossary is now visible on the page. The Study Record Dates include 'Last Update Submitted that Met QC Criteria', a 'No FEAR Act Data' section is added, and the footer shows 'Revision: v3.4.0'.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. This is a minor metadata update and does not affect study details or eligibility.SummaryDifference0.1%

- Check69 days agoChange DetectedLocations section added with sites in Arizona, California, Colorado, and Texas. The page revision updated from v3.3.2 to v3.3.3 and related location entries were adjusted.SummaryDifference0.6%

- Check97 days agoChange DetectedThe page now lists Revision: v3.3.2, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to GCS-100 Weekly Dosing in Chronic Kidney Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GCS-100 Weekly Dosing in Chronic Kidney Disease Clinical Trial page.